NON-HUMAN PRIMATE MODEL TO STUDY THE EFFECTS OF VACCINES IN PREGNANTFEMALES AND THEIR OFFSPRING NIH GUIDE, Volume 21, Number 10, March 13, 1992 RFP AVAILABLE: NIH-NIAID-DMID-93-02 P.T. 34 Keywords: Disease Model Vaccine Pregnancy Immunology National Institute of Allergy and Infectious Diseases The Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, has a requirement to develop and characterize an animal model system with special emphasis on a primate model in which to study the effects of vaccination of pregnant females on their offspring. The long-term goal of the research is to gather evidence for the safety and efficacy of maternal immunization during pregnancy for the protection of the newborn by placentally transferred antibody against frequent infant pathogens. The purpose of this research effort will be to provide baseline information, using a primate model, on a minimum of three candidate vaccines for the maternal immunization approach over the five-year period of performance. The theory behind maternal immunization is that sufficient antibody directed against bacterial or viral antigens (e.g., type-specific capsular polysaccharides of GBS and Hib or purified surface proteins of RSV) can protect against systemic infection and that antibody elicited by vaccination of pregnant women could confer protection to their infants through placental transfer. Maternal immunization could, therefore, be viewed as an approach that might provide short-term passive immunity, obviating the need for neonatal immunization when it is less likely to be effective. Indeed, there is circumstantial evidence that placentally transferred natural maternal antibody can afford protection to the offspring against infection with group B Streptococcus types III, Ib, and Ia, Hib, E. coli K1, N. meningitidis groups A and C and RSV. Passive protection of newborns for the first few months of life would bring them into an age range in which subsequent vaccination could stimulate immunity more effectively. The Request for Proposals NIH-NIAID-DMID-93-02 will be issued on or about March 24, 1992. Responses will be due by close of business June 24, 1992. It is anticipated that a completion-type contract will be awarded with incremental funding over a period of five years. Any responsible offeror may submit a proposal that will be considered by the Government. To receive a copy of this RFP, supply this office with two self-addressed mailing labels. Telephone inquiries will not be honored and all inquiries must be in writing and addressed to the office listed below: Anthony J. Murray Contracting Officer, Contract Management Branch National Institute of Allergy and Infectious Diseases The Solar Building, Room 3C07 6003 Executive Boulevard Bethesda, MD 20892 This advertisement does not commit the Government to award a contract. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |